Genetic modification of T cells improves the effectiveness of adoptive tumor immunotherapy

Archivum Immunologiae et Therapiae Experimentalis

Volumn 58, Issue 5, 2010, Pages 347-354

  Jakóbisiak, Marek ^a   Gołąb, Jakub ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Adoptive tumor immunotherapy; Gene therapy; Graft versus tumor

Indexed keywords

ALLOANTIGEN; ANTINEOPLASTIC AGENT; CANCER VACCINE; CYTOKINE; DENDRITIC CELL VACCINE; GANCICLOVIR; GLYCOPROTEIN GP 100; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELAN A; MODIFIED ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; THYMIDINE KINASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN ANTIBODY REACTION; BREAST CARCINOMA; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INVASION; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; DNA MODIFICATION; DONOR LYMPHOCYTE INFUSION; GENETIC ENGINEERING; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; SUICIDE GENE THERAPY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 77956190430     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-010-0091-0     Document Type: Review

References (108)

1. B Altvater S Landmeier S Pscherer, et al. 2009 2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells Cancer Immunol Immunother 58 1991 2001 19360406
2. B Altvater S Landmeier S Pscherer, et al. 2009 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells Clin Cancer Res 15 4857 4866 19638467
3. JE Anderson MR Litzow FR Appelbaum 1993 Allogeneic, syngeneic, and autologous marrow transplantation of Hodgkin's disease: the 21-year Seattle experience J Clin Oncol 11 2342 2350 8246023
4. A Bacigalupo M Soracco F Vassallo, et al. 1997 Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation Bone Marrow Transplant 19 927 932 9156268
5. BM Bar A Schattenberg EJ Mensink, et al. 1993 Donor lymphocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation J Clin Oncol 11 513 519 8445426
6. C Berger ME Flowers EH Warren, et al. 2006 Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation Blood 107 2294 2302 16282341
7. + T cells derived from central memory cells establishes persistent T cell memory in primates J Clin Invest 118 294 305 18060041
8. MR Bishop DH Fowler D Marchigiani, et al. 2004 Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer J Clin Oncol 22 3886 3892 15314059
9. M Bleakley S Riddell 2004 Molecules and mechanisms of the graft-versus-leukemia effect Nat Rev Cancer 4 371 380 15122208
10. A Bondanza F Ciceri C Bonini 2005 Application of donor lymphocytes expressing a suicide gene for early GVL induction and later control of GVL reactions after bone-marrow transplantation Methods Mol Med 109 475 486 15585940
11. C Bonini G Ferrari S Verzeletti, et al. 1997 HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia Science 276 1719 1724 9180086
12. C Bonini A Bondanza SK Perna, et al. 2007 The suicide gene therapy challenge: how to improve a successful gene therapy approach Mol Ther 15 1248 1252 17505474
13. V Bronte S Mocellin 2009 Suppressive influences in the immune response to cancer J Immunother 32 1 11 19307988
14. B Bruno M Rotta F Patriarca, et al. 2007 A comparison of allografting with autografting for newly diagnosed myeloma N Engl J Med 356 1110 1120 17360989
15. C Carpenito MC Milone R Hassan, et al. 2009 Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains Proc Natl Acad Sci USA 106 3360 3365 19211796
16. M Cavazzana-Calvo A Fischer 2007 Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest 117 1456 1465 17549248
17. X Chen S Regn S Raffegerst, et al. 2000 Interferon alpha in combination with GM-CSF induces the differentiation of leukemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukemic cytotoxic T-cell response from patients with chronic myeloid leukaemia Br J Haematol 111 596 607 11122108
18. BD Cheson JP Leonard 2008 Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma N Engl J Med 359 613 626 18687642
19. F Ciceri C Bonini MT Stanghellini, et al. 2009 Infusion of suicide-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukemia (the TK007 trial): a non-randomised I-II study Lancet Oncol 10 489 500 19345145
20. TM Clay MC Custer J Sachs, et al. 1999 Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity J Immunol 163 507 513 10384155
21. CJ Cohen Z Zheng R Bray, et al. 2005 Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR J Immunol 175 5799 5808 16237072
22. RH Collins Jr O Shpilberg WR Drobyski, et al. 1997 Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol 15 433 444 9053463
23. RH Collins S Goldstein S Giralt, et al. 2000 Donor leukocyte infusions in acute lymphocytic leukemia Bone Marrow Transplant 26 511 516 11019840
24. F Dazzi RM Szydlo NC Cross, et al. 2000 Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia Blood 96 2712 2716 11023502
25. AB del Campo N Aptsiauri R Méndez, et al. 2009 Efficient recovery of HLA class I expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy Scand J Immunol 70 125 135 19630918
26. A Di Stasi B De Angelis CM Rooney, et al. 2009 T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model Blood 113 6392 6402 19377047
27. CG Drake 2009 Immunotherapy for prostate cancer: walk, don't run J Clin Oncol 27 4035 4037 19635998
28. ME Dudley JC Yang R Sherry, et al. 2008 Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative J Clin Oncol 26 5233 5239 18809613
29. CE Dunbar A Larochelle 2010 Gene therapy activates EVI1, destabilizes chromosomes Nat Med 16 163 165 20134468
30. PC Emtage AS Lo EM Gomes, et al. 2008 Second generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation Clin Cancer Res 14 8112 8122 19088026
31. B Engels E Noessner B Frankenberger, et al. 2005 Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes Hum Gene Ther 16 799 810 16000062
32. European Society of Gene Therapy (2006) One of three successfully treated CGD patients in a Swiss-German gene therapy trial died due to his underlying disease: a position statement form the European Society of Gene Therapy (ESGT). J Gene Med 8:1435
33. X Feng KM Hui HM Younes, et al. 2008 Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses Trends Immunol 29 624 632 18952501
34. C Fillat M Carrió A Cascante, et al. 2003 Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application Curr Gene Ther 3 13 26 12553532
35. HM Finney AN Akbar AD Lawson 2004 Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain J Immunol 172 104 113 14688315
36. KM Frank DK Hogarth JL Miller, et al. 2009 Investigation of the cause of death in gene-therapy trial N Engl J Med 361 161 169 19587341
37. A Freedman SS Neelapu C Nichols, et al. 2009 Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma J Clin Oncol 27 3036 3043 19414675
38. H Fujisaki H Kakuda N Shimasaki, et al. 2009 Expansion of highly cytotoxic human natural killer cells for cancer cell therapy Cancer Res 69 4010 4017 19383914
39. PA Gatenby A Basten P Creswick 1981 "Sneaking through": a T-cell-dependent phenomenon Br J Cancer 44 753 756 6459113
40. S Gonzalez A Naranjo LM Serrano, et al. 2004 Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma J Gene Med 6 704 711 15170741
41. NM Haynes JA Trapani MW Teng, et al. 2002 Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors Blood 100 3155 3163 12384413
42. MH Heemskerk M Hoogeboom R Hagedoorn, et al. 2004 Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer J Exp Med 199 885 894 15051765
43. MH Heemskerk RS Hagedoorn MA van der Hoorn, et al. 2007 Efficiency of T-cell receptor expression in dual-specific T cells is controlled by intrinsic qualities of the TCR chains within the TCR-CD3 complex Blood 109 235 243 16968899
44. MM Horowitz RP Gale PM Sondel, et al. 1990 Graft-versus-leukemia reactions after bone marrow transplantation Blood 75 555 562 2297567
45. MS Hughes YY Yu ME Dudley, et al. 2005 Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions Hum Gene Ther 16 457 472 15871677
46. + T cells against NY-ESO-1 N Engl J Med 358 2698 2703 18565862
47. C Imai K Mihara M Andreansky, et al. 2004 Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia Leukemia 18 676 684 14961035
48. C Imai S Iwamoto D Campana 2005 Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells Blood 106 376 383 15755898
49. S Inogès M Rodriguez-Calvillo N Zabalegui, et al. 2006 Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma J Natl Cancer Inst 98 1292 1301 16985248
50. LA Johnson RA Morgan ME Dudley, et al. 2009 Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 114 535 546 19451549
51. R Jones R Ambinder S Piantadosi, et al. 1991 Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation Blood 77 649 653 1991174
52. MH Kershaw G Wang JA Westwood, et al. 2002 Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2 Hum Gene Ther 13 1971 1980 12427307
53. MH Kershaw JA Westwood P Hwu 2002 Dual-specific T cells combine proliferation and antitumor activity Nat Biotechnol 20 1221 1227 12415288
54. MH Kershaw JA Westwood LL Parker, et al. 2006 A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer Clin Cancer Res 12 20 Pt1 6106 6115 17062687
55. A Khammari JM Nguyen MC Pandolfino, et al. 2007 Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma Cancer Immunol Immunother 56 1853 1860 17549472
56. JN Kochenderfer SA Feldman Y Zhao, et al. 2009 Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor J Immunother 32 689 702 19561539
57. HJ Kolb J Mittermuller C Clemm, et al. 1990 Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients Blood 76 2462 2465 2265242
58. HJ Kolb A Schattenberg JM Goldman, et al. 1995 Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients Blood 86 2041 2050 7655033
59. A Kruschinski A Moosmann I Poschke, et al. 2008 Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas Proc Natl Acad Sci USA 105 17481 17486 18987320
60. + T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR Immunity 22 117 129 15664164
61. J Kuball ML Dossett M Wolfl, et al. 2007 Facilitating matched pairing and expression of TCR chains introduced into human T cells Blood 109 2331 2338 17082316
62. J Kuball B Hauptrock V Malina, et al. 2009 Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domains J Exp Med 206 463 475 19171765
63. HM Lokhorst A Schattenberg JJ Cornelissen, et al. 1997 Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation Blood 90 4206 4211 9354693
64. HM Lokhorst K Wu LF Verdonck, et al. 2004 The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma Blood 103 4362 4364 14976044
65. AW Loren DL Porter 2008 Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation Bone Marrow Transplant 41 483 493 18026156
66. J Maher S Wilkie 2009 CAR mechanics: driving T cells into the MUC of cancer Cancer Res 69 4559 4562 19487277
67. CM Mandigers JM Raemaekers AV Schattenber, et al. 1998 Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma Br J Haematol 100 198 206 9450812
68. FM Marincola P Shamamian RB Alexander, et al. 1994 Loss of HLA haplotype and B locus down-regulation in melanoma cell lines J Immunol 153 1225 1237 8027550
69. AM Marmont MM Horowitz RP Gale, et al. 1991 T-cell depletion of HLA-identical transplants in leukemia Blood 78 2120 2130 1912589
70. G Martinelli C Terragna E Zamagni, et al. 2000 Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma J Clin Oncol 18 2273 2281 10829048
71. R Mengersen R Schick E Kölsch 1975 Correlation of "sneaking through" of tumor cells with specific immunological impairment of the host Eur J Immunol 5 532 537 61875
72. MC Milone JD Fish C Carpenito, et al. 2009 Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo Mol Ther 17 1453 1464 19384291
73. RA Morgan ME Dudley YY Yu, et al. 2003 High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens J Immunol 171 3287 3295 12960359
74. RA Morgan ME Dudley JR Wunderlich, et al. 2006 Cancer regression in patients after transfer of genetically engineered lymphocytes Science 314 126 129 16946036
75. P Muranski A Boni C Wrzesinski, et al. 2006 Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go? Nat Clin Pract Oncol 3 668 681 17139318
76. No authors (1999) The increasing opacity of gene therapy. Nature 402:107
77. S Okamoto J Mineno H Ikeda, et al. 2009 Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR Cancer Res 69 9003 9011 19903853
78. JR Park DL Digiust M Slovak, et al. 2007 Adoptive transfer of chimeric antigen re-directed cytolytic T lymphocyte clones in patients with neuroblastoma Mol Ther 15 825 833 17299405
79. DL Porter MS Roth C McGarigle, et al. 1994 Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia N Engl J Med 330 100 106 8259165
80. MA Pule B Savoldo GD Myers, et al. 2008 Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma Nat Med 14 1264 1270 18978797
81. SE Raper N Chirmule FS Lee, et al. 2003 Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer Mol Genet Metab 80 148 158 14567964
82. AH Razack 2007 Bacillus Calmette-Guérin and bladder cancer Asian J Surg 30 302 309 17962138
83. M Rischer S Pscherer S Duwe, et al. 2004 Human gammadelta T cells as mediators of chimeric-receptor redirected anti-tumour immunity Br J Haematol 126 583 592 15287953
84. M Ritgen S Stilgenbauer N von Neuhoff, et al. 2004 Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR Blood 104 2600 2602 15205268
85. SA Rosenberg ME Dudley 2004 Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes Proc Natl Acad Sci USA 101 suppl 2 14639 14645 15381769
86. SA Rosenberg P Aebersold K Cornetta, et al. 1990 Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction N Engl J Med 323 570 578 2381442
87. SA Rosenberg JC Yang NP Restifo 2004 Cancer immunotherapy: moving beyond current vaccines Nat Med 10 909 915 15340416
88. NH Russell JL Byrne RD Faulkner, et al. 2005 Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haematopoietic stem cell transplantation Bone Marrow Transplant 36 437 441 15980879
89. M Sadelain R Brentjens I Rivière 2009 The promise and potential pitfalls of chimeric antigen receptors Curr Opin Immunol 21 215 223 19327974
90. SK Sankhla JS Nadkarni SN Bhagwati 1996 Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors J Neurooncol 27 133 140 8699235
91. S Stein MG Ott S Schultze-Strasser, et al. 2010 Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease Nat Med 16 198 204 20098431
92. G Suntharalingam MR Perry S Ward, et al. 2006 Cytokine storm in a phase 1 trial of the nati-CD28 monoclonal antibody TGN1412 N Engl J Med 355 1018 1028 16908486
93. Y Takahashi N Harashima S Kajigaya, et al. 2008 Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells J Clin Invest 118 1099 1109 18292810
94. S Tammana X Huang M Wong, et al. 2010 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies Hum Gene Ther 21 75 86 19719389
95. AJ Thrasher 2008 Gene therapy for primary immunodeficiencies Immunol Allergy Clin N Am 28 457 471
96. BG Till MC Jensen J Wang, et al. 2008 Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells Blood 112 2261 2271 18509084
97. CL Toze A Galal MJ Barnett, et al. 2005 Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease Bone Marrow Transplant 36 825 830 16151430
98. T Tsuji M Yasukawa J Matsuzaki, et al. 2005 Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes Blood 106 470 476 15790789
99. HW Virgin EJ Wherry R Ahmed 2009 Redefining chronic viral infection Cell 138 30 50 19596234
100. M Wadman 2007 Gene therapy might not have caused patient's death Nature 449 270 17882183
101. H Wang H Wei R Zhang, et al. 2009 Genetically targeted T cells eradicate established breast cancer in syngeneic mice Clin Cancer Res 15 943 950 19188165
102. PL Weiden N Flournoy ED Thomas, et al. 1979 Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts N Engl J Med 300 1068 1073 34792
103. LM Weiner MV Dhodapkar S Ferrone 2009 Monoclonal antibodies for cancer therapy Lancet 373 1033 1040 19304016
104. JA Westwood WK Murray M Trivett 2009 The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum J Immunother 32 292 301 19242371
105. S Wilkie G Picco J Foster, et al. 2008 Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor J Immunol 180 4901 4909 18354214
106. G Willimsky T Blankenstein 2005 Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance Nature 437 141 146 16136144
107. SH Yoon JM Lee Cho Hi, et al. 2009 Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model Cancer Gene Ther 16 489 497 19096447
108. Y Zhao Z Zheng PF Robbins, et al. 2005 Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines J Immunol 174 4415 4423 15778407